Citations

Clear

6421 citation(s) found for "Su, Christopher".

Development of an Innovative Decision-Aid to Better Align Patients’ Implantable Cardioverter Defibrillator Shock Status With Goals of Care
Chen, Christine , Godfrey, Sarah , Newcomer, Kelley , Garrett, Brenden, Zhang, Jingwen , Patel, Nakul, Viamontes, Christopher G. , Shah, Nainesh , Patel, Nimesh , Chen, Christine L , Alvarez, Kristin , Garrett, Brenden , Patel, Nakul , Viamontes, Christopher , Shah, Nainesh , Patel, Nimesh S , Sulistio, Melanie S , Godfrey, Sarah , Alvarez, Kristin , Kelly, Megan M., Sulistio, Melanie S.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | January 16, 2025 | Volume: 18 | Issue: 3 | Pages: No page available

10.1161/circoutcomes.124.011544 | PMID 39817335 Get It

Palliative Care Initiated in the Emergency Department
Siman, Nina , Adeyemi, Oluwaseun , Yamarik, Rebecca , Investigators, PRIM-ER, Bellolio, Fernanda , Bourenane, Sorayah, Brody, Abraham A. , Cameron, Lauren , Cooper, Julie J. , Deutsch, Ashley, Elsayem, Ahmed , Fleischer-Black, Jessica, Gang, Mauren, Goett, Rebecca , Heaton, Heather A. , Hill, Jacob , Isaacs, Eric, Jubanyik, Karen , Lamba, Sangeeta , Lin, Michelle , Loprinzi-Brauer, Caitlin , Madsen, Troy , Modrek, Ada, Otero, Ronny, Ouchi, Kei , Richardson, Christopher , Richardson, Lynne D. , Schoenfeld, Elizabeth , Shreves, Ashley, Tan, Audrey , Uspal, Julie, Venkat, Arvind , Walker, Laura , Wittman, Ian, Zimny, Erin, Miller, Joseph , Heaton, Heather, Bellolio, M Fernanda , Schoenfeld, Elizabeth M , Grudzen, Corita R. , Cuthel, Allison M. , Goldfeld, Keith S. , Investigators, PRIM-ER, Abella, Benjamin S. , Chodosh, Joshua , Elie, Marie‐Carmelle , Fernandez, Rosemarie , Gang, Mauren, Genes, Nicholas , Horwitz, Leora Idit , Lawrence, Katharine , Miller, Joseph S. A. , Ryan, Matthew, Shaw, Matthew, Southerland, Lauren T.

Mayo Clinic

JAMA | January 15, 2025 | Volume: 333 | Issue: 7 | Pages: 599

10.1001/jama.2024.23696 | PMID 39813042 Get It

Importance The emergency department (ED) offers an opportunity to initiate palliative care for older adults with serious, life-limiting illness. Objective To assess the effect of a multicomponent intervention to initiate palliative care in the ED on hospital admission, subsequent health care use, and survival in older adults with serious, life-limiting illness. Design, Setting, and Participants Cluster randomized, stepped-wedge, clinical trial including patients aged 66 years or older who visited 1 of 29 EDs across the US between May 1, 2018, and December 31, 2022, had 12 months of prior Medicare enrollment, and a Gagne comorbidity score greater than 6, representing a risk of short-term mortality greater than 30%. Nursing home patients were excluded. Intervention A multicomponent intervention (the Primary Palliative Care for Emergency Medicine intervention) included (1) evidence-based multidisciplinary education; (2) simulation-based workshops on serious illness communication; (3) clinical decision support; and (4) audit and feedback for ED clinical staff. Main Outcome and Measures The primary outcome was hospital admission. The secondary outcomes included subsequent health care use and survival at 6 months. Results There were 98 922 initial ED visits during the study period (median age, 77 years [IQR, 71-84 years]; 50% were female; 13% were Black and 78% were White; and the median Gagne comorbidity score was 8 [IQR, 7-10]). The rate of hospital admission was 64.4% during the preintervention period vs 61.3% during the postintervention period (absolute difference, −3.1% [95% CI, −3.7% to −2.5%]; adjusted odds ratio [OR], 1.03 [95% CI, 0.93 to 1.14]). There was no difference in the secondary outcomes before vs after the intervention. The rate of admission to an intensive care unit was 7.8% during the preintervention period vs 6.7% during the postintervention period (adjusted OR, 0.98 [95% CI, 0.83 to 1.15]). The rate of at least 1 revisit to the ED was 34.2% during the preintervention period vs 32.2% during the postintervention period (adjusted OR, 1.00 [95% CI, 0.91 to 1.09]). The rate of hospice use was 17.7% during the preintervention period vs 17.2% during the postintervention period (adjusted OR, 1.04 [95% CI, 0.93 to 1.16]). The rate of home health use was 42.0% during the preintervention period vs 38.1% during the postintervention period (adjusted OR, 1.01 [95% CI, 0.92 to 1.10]). The rate of at least 1 hospital readmission was 41.0% during the preintervention period vs 36.6% during the postintervention period (adjusted OR, 1.01 [95% CI, 0.92 to 1.10]). The rate of death was 28.1% during the preintervention period vs 28.7% during the postintervention period (adjusted OR, 1.07 [95% CI, 0.98 to 1.18]). Conclusions and Relevance This multicomponent intervention to initiate palliative care in the ED did not have an effect on hospital admission, subsequent health care use, or short-term mortality in older adults with serious, life-limiting illness. Trial Registration ClinicalTrials.gov Identifier: NCT03424109
Unilateral Versus Bilateral Endoscopic Resection of Olfactory Neuroblastoma: Pooled Analysis From Prospective and Retrospective Multicenter Data
Abiri, Arash , Nguyen, Theodore V. , Chen, Haidee , Krippaehne, Elise , Rahman, Arifeen S. , Roozdar, Pooya, Rosvall, Brandon R., Sabbaj, Michael , Adappa, Nithin D. , Chang, Eugene H., Chang, Michael T. , Kohanski, Michael A. , Hwang, Peter H. , Lee, Jivianne T. , Patel, Zara M. , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Krippaehne, Elise , Rahman, Arifeen S , Beswick, Daniel , Chang, Michael T , Choby, Garret , Eide, Jacob G. , Douglas, Jennifer E , Hwang, Peter H , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Wang, Eric W , Kuan, Edward C , Nguyen, Theodore V , Lerner, David K. , Workman, Alan D. , Wu, Shannon S. , Adappa, Nithin D. , Beswick, Daniel M. , Chang, Eugene H., Choby, Garret , Geltzeiler, Mathew , Le, Christopher H. , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D.

Mayo Clinic

International Forum of Allergy & Rhinology | January 15, 2025 | Volume: 15 | Issue: 6 | Pages: 585-593

10.1002/alr.23531 | PMID 39811891 Get It

ABSTRACTBackgroundOlfactory neuroblastoma (ONB) is a rare sinonasal malignancy primarily treated with surgery. For tumors arising from the olfactory area, traditional treatment involves transcribriform resection of the anterior cranial fossa. Surgery can be performed with unilateral or bilateral resection depending on extent of involvement; however, there are currently no studies comparing outcomes between the two.MethodsProspective and retrospective data on primary ONB patients were collected from a multicenter registry involving eight academic sites. Propensity score matching (PSM) was used to create patient cohorts with similar baseline characteristics. Cox proportional hazards and Kaplan Meier analyses assessed overall survival (OS). Logistic regression assessed associations between extent of resection (unilateral versus bilateral) and tumor recurrence or postoperative cerebrospinal fluid (CSF) leak.ResultsA total of 187 ONB patients (47.6% female) with an average age of 53.6 ± 15.1 years were analyzed. Most tumors were unilateral (81.3%) and predominantly Kadish C (58.3%) or Hyams II (55.8%). Overall, 56.7% of patients underwent bilateral resection. Fifty‐four patients experienced tumor recurrence and nine had postoperative CSF leaks. Following PSM (n = 45/group), extent of resection was not associated with mortality (hazard ratio [HR] 1.73; p = 0.407) or OS (p = 0.400). There was no association between extent of resection and recurrence (odds ratio [OR] 0.90; p = 0.814) or postoperative CSF leak (OR 1.54; p = 0.647).ConclusionsFor ONB tumors where unilateral resection may be feasible and oncologically sound, the decision for unilateral versus bilateral resection showed no significant effect on survival, recurrence, or postoperative CSF leak. Oncologic outcomes may be comparable when resection is tailored to individual patient and tumor characteristics.
US multicenter outcomes of endoscopic ultrasound-guided gallbladder drainage with lumen-apposing metal stents for acute cholecystitis
David, Yakira , Kakked, Gaurav, Confer, Bradley , Shah, Ruchit N. , Khara, Harshit S. , Diehl, David L. , Krafft, Matthew , Shah-Khan, Sardar M. , Nasr, John , Benias, Petros C. , Muniraj, Thiruvengadam , Aslanian, Harry R., Chahal, Prabhleen , Rodriguez, John , DuBroff, Jason, Latour, Rabi De, Khanna, Lauren , Haber, Gregory , Hoerter, Nicholas A. , Pandey, Nishi , Bakhit, Mena , Kowalski, Thomas E., Loren, David E. , Chiang, Austin , Schlachterman, Alexander , Nieto, Jose , Ichkhanian, Yervant , Khashab, Mouen A. , Halabi, Maan El , Kwon, Richard S. , Hernandez-Lara, Ariosto, Poneros, John M., Sethi, Amrita, Gonda, Tamas A. , Kushnir, Vladimir , Cosgrove, Natalie , Mullady, Daniel , Al-Shahrani, Abdullah , Buscaglia, Jonathan M. , Bucobo, Juan Carlos , Rolston, Vineet S. , Kedia, Prashant , Kasmin, Franklin, Kumta, Nikhil A. , DiMaio, Christopher J. , Krafft, Matthew Richard , Trindade, Arvind J. , Adler, Douglas G. , Tzimas, Demetrios J. , Goodman, Adam J. , Nieto, José , Deshmukh, Ameya A. , Prabhu, Anoop , Storm, Andrew C. , Berzin, Tyler M. , Sethi, Amrita , D'Souza, Lionel S. , Nagula, Satish

Mayo Clinic

Endoscopy International Open | January 13, 2025 | Volume: 13 | Issue: CP | Pages: No page available

10.1055/a-2495-5542 | PMID 39958659 Get It

AbstractEUS-guided gallbladder drainage (EUS-GBD) using lumen apposing metal stents (LAMS) has excellent technical and short-term clinical success for acute cholecystitis (AC). The goals of this study were to determine the long-term clinical outcomes and adverse events (AEs) of EUS-GBD with LAMS.A multicenter, retrospective study was conducted at 18 US tertiary care institutions. Inclusion criteria: any AC patient with attempted EUS-GBD with LAMS and minimum 30-day post-procedure follow-up. Long-term clinical success was defined as absence of recurrent acute cholecystitis (RAC) > 30 days and long-term AE was defined as occurring > 30 days from the index procedure.A total of 109 patients were included. Technical success was achieved in 108 of 109 (99.1%) and initial clinical success in 106 of 109 (97.2%). Long-term clinical success was achieved in 98 of 109 (89.9%) over a median follow-up of 140 days (range 30–1188). On multivariable analysis (MVA), acalculous cholecystitis (odds ratio [OR] 15.93, 95% confidence interval [CI] 1.22–208.52, P = 0.04) and the occurrence of a LAMS-specific AE (OR 63.60, 95% CI 5.08–799.29, P <0.01) were associated with RAC. AEs occurred in 38 of 109 patients (34.9%) at any time, and in 10 of 109 (9.17%) > 30 days from the index procedure. Most long-term AEs (7 of 109; 6.42%) were LAMS-specific. No technical or clinical factors were associated with occurrence of AEs. LAMS were removed in 24 of 109 patients (22%). There was no difference in RAC or AEs whether LAMS was removed or not.EUS-GBD with LAMS has a high rate of long-term clinical success and modest AE rates in patients with AC and is a reasonable destination therapy for high-risk surgical candidates.
Longitudinal FDG-PET Metabolic Change Along the Lewy Body Continuum
Przybelski, Scott A. , Lesnick, Timothy G. , Diaz‐Galvan, Patricia , Murray, Melissa M., Nguyen, Aivi T. , Reichard, Ross R., Gunter, Jeffrey L. , Jack, Clifford R. , Min, Hoon‐Ki , Jain, Manoj , Miyagawa, Toji , Forsberg, Leah K. , Fields, Julie A. , Savica, Rodolfo , Graff-Radford, Jonathan, Knopman, David S., Graff‐Radford, Neill R. , Day, Gregory S. , Ferman, Tanis J. , Kremers, Walter K. , Petersen, Ronald C., Boeve, Bradley F., Lowe, Val J. , Kantarci, Kejal, Kantarci, Kejal , St Louis, Erik K, Min, Hoon-Ki Paul , Jack, Clifford R , Kantarci, Kejal , Day, Gregory S , Ferman, Tanis J , Nguyen, Aivi T , Diaz-Galvan, Patricia , Kremers, Walter K , Ferreira, Daniel , Schwarz, Christopher G. , Dickson, Dennis W. , Senjem, Matthew L. , Graff‐Radford, Jonathan , Ramanan, Vijay K. , Jones, David T., Botha, Hugo , Louis, Erik K. St. , Petersen, Ronald C. , Boeve, Bradley F.

Mayo Clinic

JAMA Neurology | January 13, 2025 | Volume: 82 | Issue: 3 | Pages: 285

10.1001/jamaneurol.2024.4643 | PMID 39804619 Get It

Importance Although 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) is a well-established cross-sectional biomarker of brain metabolism in dementia with Lewy bodies (DLB), the longitudinal change in FDG-PET has not been characterized. Objective To investigate longitudinal FDG-PET in prodromal DLB and DLB, including a subsample with autopsy data, and report estimated sample sizes for a hypothetical clinical trial in DLB. Design, Setting, and Participants Longitudinal case-control study with mean (SD) follow-up of 3.8 (2.3) years. Cases were recruited consecutively between 2007 and 2022 at a referral center and among the population. Patients with probable DLB or mild cognitive impairment with Lewy bodies (MCI-LB) were included. Individuals without cognitive impairment were included from a population-based cohort balanced on age and sex for comparison. All participants completed at least 1 follow-up assessment by design. Exposure Patients with MCI-LB and DLB. Main Outcomes and Measures Rate of change in FDG-PET was assessed as standardized uptake value ratios (SUVr). Clinical progression was assessed with the Clinical Dementia Rating Sum of Boxes (CDR-SB) score. Results Thirty-five patients with probable DLB, 37 patients with MCI-LB, and 100 individuals without cognitive impairment were included. The mean (SD) age of the DLB and MCI-LB groups combined (n = 72) was 69.6 (8.2) years; 66 patients (92%) were men and 6 (8%) were women. At follow-up, 18 participants (49%) with MCI-LB had progressed to probable DLB. Patients with MCI-LB had a faster decline in FDG-SUVr, compared with that of participants without cognitive impairment, in the posterior cingulate, occipital, parietal, temporal, and lateral frontal cortices. The same regions showed greater metabolic decline in patients with DLB than in participants without cognitive impairment, with the addition of anterior-middle cingulate, insula, and medial frontal orbital cortices. Rates of change in FDG-PET in these brain regions were combined into a region of interest (ROI) labeled longitudinal FDG-PET LB meta-ROI. The rate of change in FDG-SUVr in the meta-ROI correlated with the rate of change in CDR-SB, and sample size estimates were reported for potential clinical trials in DLB. Findings were confirmed in the subsample with neuropathologic confirmation (n = 20). Conclusions and Relevance This study found that brain hypometabolism begins to evolve during the prodromal stages of DLB with changes paralleling symptomatic progression. These data may inform clinical practice and trials planning to use FDG-PET for biologic staging, monitoring disease progression, and potentially assessing treatment response.
Distinguishing Chronic Inflammatory Demyelinating Polyneuropathy From Mimic Disorders: The Role of Statistical Modeling
Swart, Grace , Lewis, Richard A. , Dubey, Divyanshu , Spies, Judith , Laughlin, Ruple S. , Santilli, Ashley R. , Rashed, Hebat‐Allah G, Mirman, Igal, Swart, Alexander , Berini, Sarah E. , Shouman, Kamal , Mauermann, Michelle L. , Mills, John R. , Dyck, P. James B. , Harmsen, William S. , Mandrekar, Jay , Dubey, Divyanshu , Rashed, Hebatallah R. , Skolka, Michael P , Allen, Jeffrey A , Thakolwiboon, Smathorn , Rashed, Hebatallah, Klein, Christopher J , Dubey, Divyanshu , Mauermann, Michelle L , Shelly, Shahar , Allen, Jeffrey A. , Niu, Zhiyv , Pinto, Marcus Vinícius , Klein, Christopher J.

Mayo Clinic

Journal of the Peripheral Nervous System | January 13, 2025 | Volume: 30 | Issue: 1 | Pages: No page available

10.1111/jns.12682 | PMID 39801067 Get It

ABSTRACTBackground and AimsChronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is difficult to distinguish from mimicking disorders, with misdiagnosis resulting in IVIG overutilization. We evaluate a clinical‐electrophysiological model to facilitate CIDP versus mimic neuropathy prediction.MethodsUsing the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021 CIDP guidelines we derived 26 clinical and 144 nerve conduction variables. The model was generated and validated utilizing total CIDP (n = 129) and mimics (n = 309); including (1) IgG4‐nodopathies; (2) POEMS (polyneuropathy–organomegaly–endocrinopathy–monoclonal protein‐skin changes); (3) anti‐myelin‐associated‐glycoprotein; (4) paraneoplastic; (5) Waldenström B‐cell lymphoma; (6) diabetic neuropathies; (7) amyloidosis; (8) Charcot–Marie–Tooth; (9) motor neuropathies/neuronopathies; and (10) idiopathic‐inflammatory‐myopathies.ResultsWe analyzed 9282 clinical and 51 408 electrophysiological data points. Univariate analysis identified 11 of 26 clinical variables with significant odds ratios. A multivariate regression model using four clinical and two electrophysiologic variables achieved 93% area‐under‐curve (95% CI 91–95): progression over 8 weeks (OR 40.66, 95% CI 5.31–311.36), absent autonomic involvement (OR 17.82, 95% CI 2.93–108.24), absent muscle atrophy (OR 16.65, 95% CI 3.27–84.73), proximal weakness (OR 3.63, 95% CI 1.58–8.33), ulnar motor conduction velocity slowing < 35.7 m/s (OR 5.21, 95% CI 2.13–12.76), and ulnar motor conduction block (OR 13.37, 95% CI 2.47–72.40). A web‐based probability calculator (https://news.mayocliniclabs.com/cidp‐calculator/) was developed, with 100% sensitivity and 68% specificity at a 92% probability threshold. Specificity improved to 93% when considering “red flags,” electrophysiologic criteria, and laboratory testing.InterpretationA probability calculator using clinical electrophysiological variables assists CIDP differentiation from mimics, with scores below 92% unlikely to have CIDP. The highest specificity is achieved by considering clinical “red flags,” electrophysiologic demyelination, and laboratory testing.
Role of Posterior Carbon Fiber Implants in Spine Tumor Surgery
Alvarez‐Breckenridge, Christopher , North, Robert Y. , Lo, Sheng-Fu Larry , Mohammed, Karim, Reynolds, Jeremy , Lazáry, Áron , Laufer, Ilya , Verlaan, Jorrit Jan, Gokaslan, Ziya L., Cecchinato, Riccardo , Disch, Alexander C. , Goodwin, Matthew L. , Sahgal, Arjun , Alvarez-Breckenridge, Christopher , Reynolds, Jeremy , Lazary, Aron , Disch, Alexander , Goodwin, C Rory , Tatsui, Claudio Esteves , Kumar, Naresh P. , Mohammed, Karim, Verlaan, Jorrit‐Jan , Luzzati, Alessandro , Shin, John H. , Hornicek, Francis J. , Goodwin, C. Rory , Gasbarrini, Alessandro , Boriani, Stefano

Mayo Clinic

Global Spine Journal | January 13, 2025 | Volume: 15 | Issue: 1_suppl | Pages: No page available

10.1177/21925682241259778 | PMID 39801115 Get It

Study Design Narrative Review. Objective The management of spinal tumors requires a multi-disciplinary approach including surgery, radiation, and systemic therapy. Surgical approaches typically require posterior segmental instrumentation to maintain long-term spinal stability. Carbon fiber reinforced pedicle screws (CFRP) are increasingly used in the oncologic setting due to reductions in both imaging artifacts and radiotherapy perturbations compared to titanium implants. We performed a review of the literature and highlight advantages and future areas of study for CFRP. Methods We performed a systematic review of the literature using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and identified 10 articles including 573 patients. Across all studies we reviewed patient demographics, tumor types treated, hardware-related features, complication rates, recurrence, survival, and follow-up. Results Across 10 studies, a total of 1371 screws placed. Surgical and non-surgical complications were reported in 18.3% of patients. Disease progression at the surgical site was detected in 7.3% of patients. There was no significant difference in clinical or hardware complications between CFRP or titanium implants. The most frequent complication attributable to implanted CFRP hardware included screw breakage in 2.4% and loosening in 1.7% of patients, respectively. Conclusion CFRP provide a unique tool in the setting of spinal oncology. With a safety profile comparable to titanium, we review the documented advantages of CFRP posterior implants compared to titanium, while also addressing their current limitations. Additionally, we highlight several areas of future research to identify the optimal patients who will achieve the greatest benefit of CFRP.
Patient-reported outcome trajectories the first 24 months after surgery for cervical spondylotic myelopathy: a Quality Outcomes Database study
Zeitouni, Daniel , Johnson, Sarah E. , Bisson, Erica F. , Mummaneni, Praveen V., Haid, Regis W., Chan, Andrew K. , Chou, Dean , Wang, Michael Y. , Knightly, John J. , Meyer, Scott A., Gottfried, Oren N., Shaffrey, Christopher I., Virk, Michael S. , Fu, Kai-Ming, Shaffrey, Mark E., Foley, Kevin T. , Upadhyaya, Cheerag D., Potts, Eric A. , Turner, Jay D. , Uribe, Juan S. , Tumialán, Luis M. , Coric, Domagoj , Bydon, Mohamad , Asher, Anthony L. , Ibrahim, Sufyan , Mummaneni, Praveen V. , Shaffrey, Christopher I. , Fu, Kai-Ming, Park, Paul , Uribe, Juan S.

Mayo Clinic

Journal of Neurosurgery: Spine | January 10, 2025 | Volume: 42 | Issue: 4 | Pages: 500-508

10.3171/2024.9.spine24351 | PMID 39793008 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) shows varying levels of improvement after surgical treatment. While some patients improve soon after surgery, others may take months to years to show any signs of improvement. The goal of this study was to evaluate postoperative improvement, patient-reported outcomes, and patient satisfaction up to 2 years after surgical treatment for CSM, which will help optimize the current treatment strategies and effectively manage patient expectations. METHODS This was a retrospective study of prospectively collected data using the Quality Outcomes Database. The primary outcomes of interest were achievement of the minimal clinically important difference (MCID) for the numeric rating scale for neck and arm pain, modified Japanese Orthopaedic Association, Neck Disability Index, and EQ-5D scores and postoperative satisfaction (North American Spine Society scale). Early and sustained improvement was defined as MCID achievement in at least one patient-reported outcome measure (PROM) at the 3-, 12-, and 24-month follow-ups. Transient improvement was defined as MCID achievement only at the 3-month and/or 12-month follow-up but not at the 24-month follow-up. Late improvement was defined as MCID achievement in at least one PROM only at the 24-month follow-up. RESULTS There were 630 patients included in the comparative analysis. A total of 463 (73.5%) patients achieved early and sustained improvement, 105 (16.7%) patients experienced transient improvement with subsequent decline, 25 (4.0%) patients reported late improvement, and 37 (5.9%) patients did not report any clinically meaningful improvement after surgery. Patients with an anterior approach were more likely to be in the early and sustained improvement group. African American patients (OR 2.98, 95% CI 1.14–7.76; p = 0.03) were more likely to report late improvement when compared with White patients. The overall satisfaction rate at the 24-month follow-up was 87.8%. CONCLUSIONS These findings indicate that 73.5% of patients achieve early and sustained improvement, and 87.8% of patients are satisfied with surgery 24 months postoperatively.
Prevalence, aetiology, and outcomes of native pulmonary regurgitation in the general adult population
Naser, Jwan A. , Ibrahim, Hossam, Andi, Kartik, Scott, Christopher G. , Pellikka, Patricia A. , Kennedy, Austin M , Connolly, Heidi M. , Nkomo, Vuyisile T. , Warnes, Carole A. , Jain, C. Charles , Egbe, Alexander C. , Andi, Kartik , Jain, Charles C, Borlaug, Barry A , Nkomo, Vuyisile T , Scott, Christopher , Pellikka, Patricia A , Enriquez-Sarano, Maurice , Kennedy, Austin M , Naser, Jwan A , Enriquez‐Sarano, Maurice , Pislaru, Sorin V. , Borlaug, Barry A.

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | January 10, 2025 | Volume: 26 | Issue: 4 | Pages: 695-702

10.1093/ehjci/jeaf011 | PMID 39792481 Get It

Abstract Aims Pulmonary regurgitation (PR) after reparative intervention for congenital heart disease has been studied extensively. However, the burden, distribution of causes, and outcome of PR in adults is unknown. The study aimed to evaluate the prevalence, types, and outcomes of moderate/severe PR in adults in the community setting. Methods and results A total of 398 adult residents of Olmsted County who had clinically indicated echocardiography 2004–2023 at Mayo Clinic, Rochester, and had moderate or severe PR were identified retrospectively. The median age was 77 years, 48% were females, and 61 (51%) had severe PR. The age- and sex-adjusted US prevalence was 0.11% (vs. 0.67% for ≥moderate tricuspid regurgitation). Moderate/severe PR was due to pulmonary hypertension in 77%, congenital/iatrogenic in 11%, primary pulmonary valve disease in 2% (88% due to carcinoid), and idiopathic isolated in 10%. In contrast, severe PR was due to congenital/iatrogenic disease in 52%, pulmonary hypertension in 39%, primary PR in 5%, and isolated idiopathic in 3%. The all-cause mortality rate per 100 person-year was 73 in primary (mostly carcinoid) PR, 16 in pulmonary hypertension–related PR (not different vs. propensity-matched patients without PR), and 6 in isolated idiopathic PR (not different vs. matched patients without PR). Conclusion Moderate or severe PR had a lower prevalence vs. TR. The most frequent cause was pulmonary hypertension for ≥moderate PR and congenital/iatrogenic for severe PR. Mortality in patients with acquired ≥moderate PR appeared to be related to the underlying cause, with no excess mortality compared with matched patients without PR. Whether specifically severe PR confers excess mortality requires future investigation.
In-hospital Outcomes of Ventricular Tachycardia Ablation in Patients with Primary Non-Ischemic Cardiomyopathy Versus Non-Ischemic Cardiomyopathy Secondary to Systemic Infiltrative Diseases
Sheffeh, Mohammad Ali , Sheffeh, Judy, DeSimone, Christopher V., Siontis, Konstantinos C. , Santangeli, Pasquale , Santangeli, Pasquale , Baqal, Omar J , Tabassum, Shehroze , DeSimone, Christopher V.

Mayo Clinic

No container title available | January 9, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.173645695.55110942/v1 Get It

Background: Non-ischemic cardiomyopathies can be primary (p-NICM) which involves mainly the heart muscle or caused by systemic disease with heart muscle involvement as it is seen in systemic infiltrative diseases (i-NICM). There is limited data on the safety and in-hospital outcomes of ventricular tachycardia (VT) ablation in i-NICM. Methods: We identified patients who underwent VT ablation between 2018-2021 using the National Inpatient Sample Database. i-NICM include amyloidosis, hemochromatosis, or sarcoidosis. In-hospital complications include mortality, acute kidney injury (AKI), acute heart failure (AHF), bleeding, vasopressor use, blood transfusion and cardiac tamponade. Multivariate logistic regression analyses were performed. Results : There were 7,420 VT ablations, 7,235 had P-NICM and 185 had i-NICM. A multivariable analysis did not reveal any difference in mortality (adjusted odds ratio [aOR]: 0.81; 95% confidence interval 0.32-1.98; p=0.62), AHF aOR: 0.88 (0.41-1.81; p=0.69, AKI aOR:1.17 (0.83-1.65); p=0.36, blood transfusion aOR: 0.63 (0.25-1.59); p=0.33, vasopressor aOR: 0.86( 0.51-1.49); p=0.61 or pericardial effusion/ tamponade aOR: 1.16 (0.67-2.1); p=0.58 Figure Conclusion: Patients with i-NICM had similar in-hospital complications compared to P-NICM further supporting the safety of VT ablation in managing recurrent VT in patients with i-NICM.